The JoPIC is an independent-unbiased, peer-reviewed, and open-access journal of current national and international issues and reviews for original clinical and experimental research, interesting case reports, surgical techniques, differential diagnoses, editorial opinions, letters to the editor, and educational papers in pulmonology, thoracic surgery, occupational diseases, allergology, and intensive care medicine. This journal is indexed by indices that are considered international scientific journal indices (DRJI, ESJI, OAJI, etc.). According to the current Associate Professorship criteria, it is within the scope of International Article 1-d. Each article published in this journal corresponds to 5 points.

EndNote Style
Original Article
The role of clinical pulmonary infection score and some infection biomarkers in diagnosis and follow up in hospital acquired pneumonia
Aims: Early diagnosis and treatment affect mortality in hospital-acquired pneumonia (HAP). Therefore, clinicians need some objective parameters for guiding treatment. The aim of this study was to determine the course of ‘‘clinical pulmonary infection score’’ (CPIS), C-reactive protein (CRP) and procalcitonin (PCT) in patients under treatment as well as the relationship of these parameters with each other and mortality.
Methods: This single-center, prospective, cross-sectional study focused on cases of HAP in hospitalized patients. In patients with HAP; CPIS, CRP and PCT assays were assessed on the first day. Appropriate treatment was initiated according to Turkish Thoracic Society HAP Task Force recommendations. On the 3rd day, CPIS evaluation and on the 4th day CRP and PCT analysis were repeated. All the patients’ one month mortality rates were recorded.
Results: Among the 25 patients, there were 14 females. The mean age was 66±15 years. The mean duration for HAP development was 9.4±8.2 days. With a cutt-off value of 65 for age CPIS, CRP, PCT, length of hospital stay and mortality rate was not found different (p>0.05), however as the age increased HAP development duration significantly decreased (r=-0.416, p=0.03). We demonstrated a significant change between the first and the follow-up values of fever (p=0.046), leukocyte (p<0.001), PaO2/FiO2 (p=0.016), secretion presence (p<0.001), culture positivity (p<0.001) as well as total CPIS (p=0.030). However, there wasn’t a significant difference in CRP and PCT levels. We couldn’t show any relation between CPIS domains, total CPIS, CRP, PCT, HAP development duration and mortality rates.
Conclusion: Monitoring HAP treatment according to CPIS was found better than CRP and PCT. However, these parameters had no effect on mortality. For more accurate comments, studies with more patients are needed.

1. American thoracic society: guidelines for the management of adultswith hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
2. Seligman R, Meisner M, Lisboa T, et al. Decreases in procalcitoninand C-reactive protein are strong predictors of survival in ventilator-associated pneumonia. Crit Care. 2006; 10(5):1-9.
3. Kılın&ccedil; O, Arman D, Bacakoğlu F, et al. T&uuml;rk Toraks Derneğierişkinlerde hastanede gelişen pn&ouml;moni tanı ve tedavi uzlaşı raporu.T&uuml;rk Toraks Derg. 2009;10(6):1-24.
4. T&uuml;rk Toraks Derneği Erişkinlerde Hastanede Gelişen Pn&ouml;moni Tanı VeTedavi Uzlaşı Raporu. T&uuml;rk Toraks Dergisi. 2018;p1.
5. Pugin J, Auckenthaler R, Mili N, Janssens JP, Lew PD, Suter PM.Diagnosis of ventilator-associated pneumonia by bacteriologic analysisof bronchoscopic and nonbronchoscopic &ldquo;blind&rdquo; bronchoalveolarlavage fluid. Am Rev Respir Dis. 1991;143(5 Pt 1):1121-1129.
6. Akalın H, &Ouml;zakın C, Kahveci F, et al. Hastanede gelişen pn&ouml;moniler.Flora. 1999;4:253-257.
7. Tablan OC, Anderson LJ, Besser R, et al. Guidelines for preventinghealth-care-associated pneumonia, 2003: recommendations of CDCand the Healthcare Infection Control Practices Advisory Committee.MMWR Recomm Rep. 2004;53(RR-3):1-36.
8. Fortaleza CM, Abati PA, Batista MR, Dias A. Risk factors for hospital-acquiredpneumonia in nonventilated adults. Braz J Infect Dis. 2009;13(4):284-288.
9. Kalil AC, Metersky ML, Klompas M, et al. Management of adults withhospital-acquired and ventilator-associated pneumonia: 2016 clinicalpractice guidelines by the infectious diseases society of America andthe American thoracic society. Clin Infect Dis. 2016;63(5):e61-e111.
10. DiPasquale M, Aliberti S, Mantero M, et al. Non-intensive care unitacquired pneumonia: a new clinical entity? Int J Mol Sci. 2016;17(3):287.
11. Dandagi GL. Nosocomial pneumonia in critically ill patients. LungIndia. 2010;27(3):149-153. doi:10.4103/0970-2113.68321
12. Gastmeier P, Sohr D, Geffers C, Behnke M, R&uuml;den H. Risk factorsfor death due to nosocomial infection in intensive care unit patients:findings from the Krankenhaus Infektions Surveillance System. InfectControl Hosp Epidemiol. 2007;28(4):466-472.
13. Napolitano LM. Use of severity scoring and stratification factorsin clinical trials of hospital-acquired and ventilator-associatedpneumonia. Clin Infect Dis. 2010;51(1):S67-S80.
14. Dom&iacute;nguez AA, Arango MV, Torres A. Treatment failure in patientswith ventilator-associated pneumonia. Semin Respir Crit Care Med.2006;27(1):104-114.
15. Vall&eacute;s J, Mesalles E, Mariscal D, et al. A 7-year study of severe hospital-acquired pneumonia requiring ICU admission. Intensive Care Med.2003;29(11):1981-1988.
16. Deng Z, Hu BJ, He LX, et al. A multicenter prospective cohort study onrisk factors for hospital-acquired pneumonia in the elderly. ZhonghuaNei Ke Za Zhi. 2008;47(1):31-35.
17. Hilker R, Poetter C, Findeisen N, et al. Nosocomial pneumonia afteracute stroke: implications for neurological intensive care medicine.Stroke. 2003;34(4):975-981.
18. Shorr AF, Cook D, Jiang X, Muscedere J, Heyland D; Canadian CriticalCare Trials Group. Correlates of clinical failure in ventilator-associatedpneumonia: insights from a large, randomized trial. J Crit Care. 2008;23(1):64-73.
19. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator-associated pneumonia: prospective evaluation of the clinical pulmonaryinfection score as an early clinical predictor of outcome. Crit Care Med.2003;31(3):676-682.
20. Swoboda SM, Dixon T, Lipsett PA. Can the clinical pulmonary infectionscore impact ICU antibiotic days? Surg Infect (Larchmt). 2006;7(4):331-339.
21. Sathitakorn O, Chansirikarnjana S, Jantarathaneewat K, et al. Therole of procalcitonin and clinical pulmonary for infection score(CPIS) score to reduce inappropriate antibiotics use among moderateto severe coronavirus disease 2019 (COVID-19) pneumonia: aquasi-experimental multicenter study. Infection Control &amp; HospitalEpidemiology. 2023;44(7):1199-1203.
22. Vincent JL, Rello J, Marshall J, et al. International study of theprevalence and outcomes of infection in intensive care units. JAMA.2009;302(21):2323-2329.
23. Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J. Serumprocalcitonin and C-reactive protein levels as markers of bacterialinfection: a systematic review and meta-analysis. Clin Infect Dis.2004;39(2):206-217.
24. Holm A, Pedersen SS, Nexoe J, et al. Procalcitonin versus C-reactiveprotein for predicting pneumonia in adults with lower respiratory tractinfection in primary care. Br J Gen Pract. 2007;57(540):555-560.
25. Zheng N, Zhu D, Han Y. Procalcitonin and C-reactive protein performbetter than the neutrophil/lymphocyte count ratio in evaluatinghospital acquired pneumonia. BMC Pulm Med. 2020;20(1):1-10.
26. Ramirez P, Garcia MA, Ferrer M, et al. Sequential measurements ofprocalcitonin levels in diagnosing ventilator-associated pneumonia.Eur Respir J. 2008;31(2):356-362.
27. Lim SC, Doshi V, Castasus B, Lim JK, Mamun K. Factors causing delayin discharge of elderly patients in an acute care hospital. Ann Acad MedSingap. 2006;35(1):27-32.
Volume 1, Issue 4, 2023
Page : 79-85